Tinazole

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tinazole

What is Tinazole?

Tinazole is an anti-infective medication containing the active ingredient tinidazole. It belongs to a class of drugs known as nitroimidazoles, which are primarily used to treat infections caused by specific types of bacteria and certain parasites.

Mechanism of Action

The medication works by entering the cells of microorganisms and interfering with their DNA. By disrupting the genetic material, it prevents the pathogens from reproducing and functioning, effectively stopping the spread of the infection within the body.

Primary Uses

Tinazole is used to manage various conditions where susceptible organisms are present. These typically include:

  • Protozoal Infections: It is commonly used for infections such as trichomoniasis, giardiasis, and amebiasis (including amebic liver abscesses).
  • Bacterial Vaginosis: It is utilized to treat certain bacterial imbalances in the vaginal flora.
  • Anaerobic Bacterial Infections: It may be used for specific systemic or localized infections caused by bacteria that thrive in environments without oxygen.

Because Tinazole is an antibiotic and antiprotozoal agent, it is only effective against specific types of infections. It does not treat viral infections, such as the common cold or the flu.

Regulatory References

  1. NIH LiverTox
  2. WHO Essential Medicines
  3. NIH DailyMed

What side effects are possible with Tinazole?

Official Safety Profile and Adverse Reactions

The official safety profile for Tinazole organizes potential effects into System-Organ-Classes (SOC) based on authoritative regulatory documents. Adverse reactions are classified by frequency, ranging from Most Common to those where the frequency is Not Known.

Key areas for side effects include Gastrointestinal Disorders (e.g., metallic taste, nausea, vomiting, abdominal cramps, anorexia, headache, dizziness) and Nervous System Disorders.


Serious Adverse Reactions and Safety Constraints

Specific warnings in regulatory labels highlight the potential for rare but clinically significant events. These Serious Adverse Reactions include Peripheral Neuropathy (which can manifest as numbness, tingling, or weakness) and Convulsive Seizures, both of which may require prompt discontinuation of the medicine. Severe hypersensitivity reactions, such as Angioedema, are also documented safety concerns.


Population-Specific Limitations

Regulatory documents establish several constraints. Tinazole is generally considered contraindicated during the first trimester of pregnancy and in individuals with pre-existing organic neurological disorders. Additionally, a critical safety restriction requires the avoidance of all alcoholic beverages during therapy and for at least 72 hours (3 days) after the final dose to prevent a severe disulfiram-like reaction.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents describe the profile of Tinidazole overdose primarily based on potential adverse effects. Reports of human overdose are considered anecdotal and may not provide consistent data regarding clinical signs and symptoms. However, significant ingestion has been associated with neurological disturbances.

The most serious manifestations associated with high-dose scenarios include the development of ataxia (uncoordinated movements) and peripheral neuropathy (nerve damage). The official guidance mandates that individuals must seek immediate medical attention or call a Poison Control Center if an overdose is suspected. Urgent medical services should be contacted if the affected individual collapses, has a seizure, experiences difficulty breathing, or cannot be awakened.

Overdose Management

No specific antidote is known for the treatment of Tinidazole overdosage. Consequently, treatment is officially defined as symptomatic and supportive. Regulatory information indicates that management may include general supportive measures. Gastric lavage may be considered as a procedural measure, and hemodialysis can be an effective intervention, as it is known to significantly reduce the amount of the drug in the systemic circulation. Close clinical monitoring is required, especially for the observation of neurological signs.

Therapeutic Uses of Tinazole

What Tinazole treats: main uses and benefits

Tinazole is commonly used to help with conditions caused by specific susceptible protozoa and anaerobic bacteria, supports symptomatic management across several key domains. This medication is indicated for the treatment of trichomoniasis, giardiasis, amebiasis, and bacterial vaginosis.

Tinazole is applied across domains where additional symptomatic support is needed related to protozoal gastrointestinal illness and urogenital infections. This therapeutic approach is relevant for easing symptoms that interfere with daily functioning and create noticeable physiological strain, which often occurs during conditions characterized by periods of heightened symptoms.

“The therapeutic support is relevant when supportive symptom management is appropriate, helping to maintain a sense of stability when symptoms are more noticeable.”

In cases of protozoal gastrointestinal illness, this action may assist with managing symptoms related to physical discomfort and contributes to easing the overall symptom load of manifestations like diarrhea and cramps. In urogenital contexts, it supports patients during episodes of heightened discomfort, and may assist with maintaining functional stability. It is also applied in contexts involving heightened systemic burden associated with certain anaerobic manifestations.


Quick Fact: Support for Gastrointestinal Symptoms

Tinazole is relevant for managing symptom clusters that may become intense or disruptive, especially those linked to protozoal infections causing acute diarrhea and abdominal cramping. It helps improve day-to-day comfort during periods of heightened symptoms.

Regulatory References

  1. NIH DailyMed

Eligibility and Restrictions for Use

Who Can and Cannot Use Tinazole?

The population eligibility for using Tinazole (Tinidazole) is strictly defined by regulatory authorities and is based on age, pre-existing conditions, and physiological status.


Contraindicated Populations

The medicine is contraindicated (must not be used) in patients with a history of hypersensitivity to Tinidazole or any other 5-nitroimidazole derivative (e.g., Metronidazole). Use is also prohibited during the first trimester of pregnancy and in patients with Cockayne Syndrome.


Age and Condition Restrictions

Population Group Official Regulatory Status
Pediatric (≤ 3 years) Safety and effectiveness have not been established.
Pediatric (> 3 years) Approved for Giardiasis and Amebiasis only.
Severe Hepatic Impairment Use with caution (conditional use).
Blood Dyscrasia Use with caution (conditional use).
Active CNS Disorders Contraindicated/Avoidance required.

Pregnancy and Lactation: Use in the second and third trimesters of pregnancy is permitted only if the potential benefits outweigh the possible hazards. For nursing mothers, the medicine is not recommended, and breastfeeding must be interrupted for 72 hours after the final dose.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Tinazole may interact with various medicines and substances, potentially altering the effects of either Tinazole or the co-administered agent, as documented in official regulatory labeling.

Clinically Significant Drug-Drug Interactions

Interacting Product Category Official Regulatory Statement
Oral Anticoagulants (e.g., Warfarin) Dosage adjustment of the anticoagulant may be required, necessitating close monitoring of anticoagulant activity (e.g., INR) during and for several days following Tinazole therapy.
Lithium Use with caution; monitoring of serum lithium concentrations is required to manage potential toxicity.
Immunosuppressants (e.g., Cyclosporine, Tacrolimus) Monitoring for increased toxicity of the immunosuppressant agent is required.
Anticonvulsants (e.g., Phenytoin) Adjustment of the anticonvulsant and/or Tinazole dose may be necessary.
CYP3A4 Modifiers Concomitant use with strong inhibitors or inducers of the CYP3A4 enzyme may necessitate monitoring for changes in Tinazole plasma concentrations.

Interactions with Alcohol and Related Products

Alcohol and Propylene Glycol must be strictly avoided during treatment with Tinazole and for a minimum of three days (72 hours) after the last dose. This constraint is officially documented due to the risk of a disulfiram-like reaction.

Mechanism of Action

Prodrug Activation and Selective Toxicity

Tinidazole functions through a mechanism of selective toxicity, acting as a prodrug that requires chemical activation to exert its lethal effect. The drug is inert until it enters the target microbial cell, which contains low-redox potential electron transport proteins, such as ferredoxin. These enzymes reduce the drug's nitro group ( NO2), generating highly reactive nitro radical anions.

Mechanistic Damage to Microbial DNA

The generated nitro radicals immediately initiate a cytotoxic cascade, primarily targeting the microbe's DNA. The radicals cause irreparable damage, including strand breaks and disruption of the helical structure. This action immediately suppresses nucleic acid synthesis and halts the cell's ability to replicate and repair itself. The physiological consequence of this damage is irreversible microbial cell death (a microbicidal effect).

Constraints of the Redox Environment

The mechanism is intrinsically constrained by the environment. The presence of oxygen acts as a scavenger of the toxic radicals, making the drug largely ineffective against aerobic bacteria. Furthermore, resistance may emerge if the pathogen's reductase pathways are altered, which restricts the drug's activity to specific anaerobic physiological settings.

Dosage and Administration Information

How to Use Tinazole

The usage of Tinazole is structured around specific, short-term, label-mandated administration protocols, utilizing the oral route for all approved applications. The medication is primarily supplied as film-coated tablets; however, an extemporaneously compounded oral suspension can be prepared for administration to patients unable to swallow the solid dosage form.


Official Administration Guidelines

Instruction Domain Official Regulatory Guidance
Route of Administration The oral route is the sole approved method, using tablets or suspension.
Timing in Relation to Meals Administration must occur with food (during or shortly after a meal) to mitigate potential gastrointestinal discomfort.
Dosing Schedule & Frequency Regimens involve either a single 2 g dose (e.g., for Giardiasis and Trichomoniasis) or multi-day courses of 1 g or 2 g once daily (for Bacterial Vaginosis and Amebiasis).
Course Duration The medication is used for fixed, short-term courses, typically lasting from a single day up to a maximum of five days.

Population-Specific Use and Procedural Conditions

Usage instructions incorporate adjustments for specific patient groups. For pediatric patients three years of age and older, the official dosing for Giardiasis and Amebiasis is calculated on a weight-based schedule at 50 mg/kg/day, up to a maximum of 2 g per day. Patients on hemodialysis require an additional one-half dose of the recommended amount after the session if the dose was taken prior to dialysis. A mandatory procedural condition for the treatment of Trichomoniasis is the simultaneous treatment of the sexual partner.

Recent Clinical Evidence

Research evidence / Overview of studies for Tinazole


Evidence for Use in Trichomoniasis

Research primarily includes Randomized Controlled Trials (RCTs) and comparative studies, applied in exploring how symptoms change over time. Investigators focused on outcomes related to the measured absence of the organism (T. vaginalis) and patient-reported discomfort. Research describes patterns related to the measured absence of the organism, often consistent with other comparative treatments. However, the evidence relies on older trials, and long-term effects are not fully established, limiting insight into sustained outcomes.


Evidence for Use in Giardiasis

The research base includes RCTs, comparative trials, and Network Meta-analyses (NMA). These studies explored treatment for conditions associated with physical discomfort and functional limitations. Research examined therapeutic cure, combining the measured clearance of the organism from stool and the clinical reporting of symptoms. Data show patterns related to measured microbiological outcomes in the populations studied. Despite the volume of research, data for long-term outcomes regarding sustained resolution or recurrence prevention is limited.


Evidence for Other Approved Uses

Studies have also established the research base for Amebiasis and Bacterial Vaginosis (BV). Research on Amebiasis relies on historical multi-center open trials that examined parasitological clearance in adults and children. For BV, research consists of placebo-controlled RCTs that monitored therapeutic cure based on established clinical criteria. Findings were mixed in some comparative research against other alternatives. In both contexts, the evidence quality varies, and comparative evidence is lacking for a comprehensive picture against every alternative.


Specialized Research and Evidence Gaps

Research explored the use of the medication in children aged three years and older (for Amebiasis and Giardiasis) and in men treated as sexual partners. In these specialized groups, research provides insight into short-term changes; however, sample sizes were modest. The final research record indicates several limitations: long-term effects are not fully established across all conditions, and the foundational data for some uses is reliant on older research where modern blinding standards were not consistently applied.

Key Studies & References

  1. Tinidazole Oral Tablet FDA Label (DailyMed)
  2. Tinidazole (LiverTox, NIH) - Drug Record
  3. WHO Model List of Essential Medicines (Relevant for global use context)

Frequently Asked Questions (FAQ)

Common questions about Tinazole (FAQ)

Q: What happens if I miss a dose of Tinazole?

Official regulatory documents state that if a dose is missed, it should be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed one should be skipped. It is important that doses are not doubled to make up for a forgotten one.

Q: Are there any common foods or drinks to avoid while using Tinazole?

Specific common foods are not listed as forbidden in the official product information. However, due to the risk of a severe reaction, official product information requires the strict avoidance of all alcoholic beverages and products containing propylene glycol or alcohol during treatment and for 72 hours (three days) after the final dose.

Q: Are the side effects of Tinazole usually severe?

Many of the adverse reactions, such as metallic taste and nausea, are classified as common and are generally reported as mild and temporary. However, the official safety profile also includes warnings for rare but serious adverse reactions, such as peripheral neuropathy (nerve damage) or seizures, that require immediate medical attention.

Q: Is there a generic version of Tinazole available?

Yes, Tinazole is the international non-proprietary name (INN) for the active ingredient. Generic versions of Tinidazole are approved by regulatory authorities and are available from various manufacturers.

Q: Can children take Tinazole?

Official regulatory documents indicate that the safety and effectiveness of Tinazole have not been established for children 3 years of age and younger. For children older than 3 years, the medicine is approved only for the treatment of Giardiasis and Amebiasis and is administered at a weight-based dose.

Q: Does Tinazole affect birth control pills?

Official regulatory documents, including the drug interaction sections, do not list a known interaction between Tinazole and oral contraceptives (birth control pills) that requires a specific warning or dosage change.

Q: Is a metallic taste in the mouth a known side effect of Tinazole?

Yes, official safety information documents that a sharp or unpleasant metallic taste in the mouth is one of the most common side effects that may be experienced during Tinazole therapy.

Q: Can Tinazole cause a headache?

Yes, headache is officially documented in the list of common side effects associated with Tinazole use reported in regulatory documents.

Q: How is Tinazole different from standard antibiotics?

Tinazole belongs to the nitroimidazole class of anti-infectives, giving it a unique mechanism. Unlike many standard antibiotics, it is a prodrug that is activated only inside susceptible microbial cells, which makes its action highly selective against specific protozoa and anaerobic bacteria.

Q: Can Tinazole be crushed or chewed?

The drug is supplied as film-coated tablets designed to be swallowed whole. An oral suspension can be prepared by a pharmacist for those who have trouble swallowing, but there are no official instructions permitting the tablets to be routinely crushed or chewed for administration.

Q: Does taking Tinazole require lifestyle changes?

The most significant restriction is the strict avoidance of alcohol and products containing propylene glycol, which is mandated by safety documents during the full course of therapy and for 72 hours afterward.

Q: What is the purpose of the 'inactive ingredients' in a Tinazole tablet?

The inactive ingredients, or excipients, are non-medicinal substances required to manufacture the tablet. Their purpose is to help give the tablet bulk, ensure stability, facilitate the coating, and help deliver the active ingredient (Tinazole) properly into the body.

Q: Does Tinazole cause fatigue or tiredness?

Yes, official safety information documents fatigue or feelings of weakness and tiredness among the list of common side effects reported during the use of Tinazole.

Q: Are there long-term side effects associated with Tinazole use?

Tinazole is used for fixed, short-term courses, often lasting only a few days, so long-term side effects are not routinely reported in the context of brief courses. However, the regulatory documents warn of rare, serious effects like Peripheral Neuropathy (nerve damage) that could potentially require longer-term monitoring.

Q: Is Tinazole appropriate for people with kidney problems?

Regulatory information indicates conditional use for those with kidney issues. Patients undergoing hemodialysis may require a specific dose adjustment (an additional half-dose) administered after the dialysis session. The presence of general kidney problems does not typically require a dose change for patients not on dialysis.

Q: What official studies address the duration of treatment with Tinazole?

Studies referenced in the official regulatory labels, such as Randomized Controlled Trials (RCTs) for various infections, evaluated the drug using fixed, short-term regimens (e.g., single-dose or 2–5 day courses). These studies were used to determine the shortest and most effective treatment duration for each approved condition.

Q: Does Tinazole cause any emotional or mood changes?

Official safety documents list Nervous System Disorders as a category of adverse reactions. Specific rare side effects that have been reported include depression and generalized changes in mood or mental state.

Q: Why does the information sheet mention avoiding certain over-the-counter products with Tinazole?

The restriction on some over-the-counter products is directly linked to the need to strictly avoid alcohol (ethanol) and propylene glycol. These are common ingredients in various products like cough syrups, mouthwashes, and tonics, which can trigger a severe interaction when combined with Tinazole.

Q: How quickly should I start to feel better after taking Tinazole?

Official regulatory documents do not specify a fixed timeframe for the onset of relief, as this varies by individual and infection type. Since Tinazole is prescribed for short, fixed courses, clinical trials focused on clearing the infection, but many patients may begin to observe changes within the first few days of therapy.

Q: How long does Tinazole stay in your system?

The drug is eliminated from the body slowly, which is why alcohol must be avoided for at least 72 hours (three days) after the final dose. Its chemical properties allow it to stay in the body longer than some similar medicines, supporting its use in short-course treatments.

Q: Is Tinazole safe for use during pregnancy?

Official regulatory information clearly states that the medicine is contraindicated (must not be used) during the first trimester of pregnancy. Use during the second and third trimesters is permitted only when the documented potential benefits are considered to outweigh the possible hazards.

Q: What are the official warnings about taking Tinazole while breastfeeding?

Due to the potential for the drug to pass into breast milk, official warnings state that the medicine is not recommended for nursing mothers. If it is used, breastfeeding must be interrupted for 72 hours after the final dose to allow the drug to clear the mother's system.

Q: Is it true that alcohol is strictly forbidden with Tinazole?

Yes, official regulatory documents require that alcohol be strictly avoided during treatment and for at least 72 hours (three days) following the last dose to prevent a severe disulfiram-like reaction.

Q: What is the difference between Tinazole and similar drugs like Metronidazole?

Both Tinazole and Metronidazole are in the nitroimidazole class and treat similar infections. Official information suggests their overall efficacy and spectrum are similar, but Tinazole has a different pharmacokinetic profile (how the body handles the drug), which often supports shorter treatment periods.

How should Tinazole be stored and disposed of?

How to Store and Dispose of Tinidazole

Tinidazole tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted excursions to 30 C (86 F). The product must be protected from light and moisture and should not be frozen.

Storage and Handling

  • Child Safety: The medication must be kept out of the reach of children, often supplied with a child-resistant cap.
  • Prepared Suspension: An extemporaneously prepared oral suspension is stable for only 7 days when stored at room temperature.

Disposal

  • Unused Product: Unused or expired Tinidazole should be returned to a drug take-back program.
  • Household Disposal: If a take-back program is unavailable, the product should be mixed with an undesirable substance, sealed in a bag, and then placed in the household trash; it should not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tinazole found in:

A-Z Index: